| 23.99 0.01 (0.04%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.03 | 1-year : | 32.74 |
| Resists | First : | 24 | Second : | 28.03 |
| Pivot price | 23.97  |
|||
| Supports | First : | 23.4 | Second : | 23.04 |
| MAs | MA(5) : | 23.98 | MA(20) : | 23.96 |
| MA(100) : | 23.02 |
MA(250) : | 19.37 |
|
| MACD | MACD : | 0.1  |
Signal : | 0.2 |
| %K %D | K(14,3) : | 86.3 |
D(3) : | 86.9 |
| RSI | RSI(14): 73.1 | |||
| 52-week | High : | 25.31 | Low : | 12.47 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ABCM ] has closed below upper band by 33.0%. Bollinger Bands are 93.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 24.05 - 24.16 | 24.16 - 24.26 |
| Low: | 23.65 - 23.82 | 23.82 - 23.95 |
| Close: | 23.76 - 24.01 | 24.01 - 24.21 |
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.
Fri, 17 Nov 2023
Abcam Acquisition by Danaher has Received all Identified Clearances; Transaction Expected to Close on December 6 ... - Abcam plc
Mon, 06 Nov 2023
Shareholders of Abcam Approve Proposed Acquisition by Danaher – Abcam plc - Abcam plc
Thu, 19 Oct 2023
She Blinded Me with Science – ISS Makes Schoolboy Error on Abcam Deal - Yahoo Finance
Thu, 05 Oct 2023
Abcam files and mails Scheme Circular seeking approval of acquisition of Abcam by Danaher for $24.00 per share ... - Abcam plc
Thu, 21 Sep 2023
Headwaters Capital Calls Out Fishy Bid for Abcam from Danaher in Letter to Stakeholders – Exclusive - Yahoo Finance
Wed, 20 Sep 2023
Abcam founder considering options to regain company amid takeover - report - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 230 (M) |
| Shares Float | 192 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 88.2 (%) |
| Shares Short | 4,080 (K) |
| Shares Short P.Month | 2,900 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.14 |
| Profit Margin | 0.6 % |
| Operating Margin | 18.3 % |
| Return on Assets (ttm) | 4.3 % |
| Return on Equity (ttm) | 0.3 % |
| Qtrly Rev. Growth | 9.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.64 |
| EBITDA (p.s.) | 0.46 |
| Qtrly Earnings Growth | 188 % |
| Operating Cash Flow | 26 (M) |
| Levered Free Cash Flow | 29 (M) |
| PE Ratio | 2399 |
| PEG Ratio | 0 |
| Price to Book value | 7.64 |
| Price to Sales | 14.54 |
| Price to Cash Flow | 210.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|